Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | GLB1 | P16278 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322680 | 0.94 | ALOX5 (0.36) | CNR2GBA1ALOX5 | |
| SCHEMBL6330284 | 0.93 | ALOX5 (0.39) | GBA1ALOX5 | |
| SCHEMBL6324604 | 0.85 | CYP1A2 (0.42) | CYP1A2LMNAMAPK1HTTGLB1 | |
| SCHEMBL6325426 | 0.83 | THRA (0.33) | — | |
| SCHEMBL6322643 | 0.81 | ALOX5 (0.42) | GBA1ALOX5 | |
| SCHEMBL6325295 | 0.79 | ALOX5 (0.46) | GBA1ALOX5 | |
| SCHEMBL6327475 | 0.79 | ALOX5 (0.46) | GBA1ALOX5 | |
| SCHEMBL6331129 | 0.79 | ALOX5 (0.44) | GBA1ALOX5 | |
| SCHEMBL12166615 | 0.77 | CA1 (0.46) | CYP1A2LMNAMAPK1HTTGLB1 | |
| SCHEMBL6401737 | 0.77 | ALOX5 (0.47) | GBA1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | ZEON CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1420005-A1 | CYCLOPENTANONE DERIVATIVE | Zeon Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | PTGIS, CYP51A1, TRPA1 | CYP1A2 57/4885CNR2 69/4885LMNA 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.